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1-sentence condensation of the paper:  
Population testing for BRCA mutations is cost-effective in UK & US Ashkenazi Jewish women >30 
years with varying levels of Jewish ancestry: one, two, three, four AJ grandparents. 
 
Shortened Title: 
Cost-effectiveness of population BRCA testing with varying Jewish ancestry 
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Abstract: 
Background 
Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to family-
history based testing in Ashkenazi-Jewish (AJ) women >30years with four AJ-grandparents. However, 
individuals may have one, two or three AJ grandparents and cost-effectiveness data are lacking at 
these lower BRCA prevalence estimates. We present an updated cost-effectiveness analysis of 
population BRCA1/BRCA2 testing for women with one, two and three AJ grandparents. 
Methods  
Life time costs and effects of population and family-history based testing were compared using a 
decision analysis model. 56% BRCA carriers are missed by family-history criteria alone. Analyses are 
conducted for UK and USA populations. Model parameters are obtained from the GCaPPS trial and 
published literature. Model parameters and BRCA population prevalence for individuals with three, 
two or one AJ grandparents are adjusted for the relative frequency of BRCA mutations in the AJ and 
general populations. Incremental cost-effectiveness ratios were calculated for all AJ-grandparent 
scenarios. Costs along with outcomes discounted at 3.5%. The time horizon of the analysis is ‘life-
time’ and perspective is ‘payer’. Probabilistic sensitivity-analysis (PSA) evaluated model uncertainty.   
Results 
Population testing for BRCA mutations is cost saving in AJ women with two, three or four 
grandparents (22-33 days life-gained) in UK and one, two, three or four grandparents (12-26 days 
life-gained)  in USA populations respectively. It is also extremely cost-effective in UK women with 
just one AJ-grandparent with an incremental-cost-effectiveness-ratio (ICER)= £863/QALY and 15days 
life-gained. Results show that population-testing remains cost-effective at the £20,000-30000/QALY 
and $100,000/QALY willingness-to-pay thresholds for all four AJ-grandparent scenarios with ≥95% 
simulations found to be cost-effective on PSA. Population-testing remains cost-effective in the 
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absence of reduction in breast cancer risk from oophorectomy and at lower RRM (13%)/RRSO (20%) 
rates. 
Conclusions 
Population-testing for BRCA mutations is cost-effective in the UK and USA with varying levels of AJ 
ancestry. These results support population testing in AJ women with 1-4 AJ-grandparent ancestry.  
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Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish 
ancestry 
 
INTRODUCTION 
 
Population-based BRCA1/BRCA2 testing has been extensively investigated in the Ashkenazi-Jewish 
(AJ) population and shown to have several advantages compared to family-history (FH) based 
testing.  FH based testing requires individuals to fulfil stringent clinical criteria but many 
BRCA1/BRCA2 carriers do not meet this clinical threshold for genetic testing based on cancer history 
in the family. This approach results in over 50% of additional at-risk carriers being missed by FH 
driven clinical criteria based testing.1, 2 Randomised trial data show that population-testing does not 
detrimentally impact psychological well-being or quality-of-life.2 There is an overall reduction in 
anxiety, distress, and uncertainty,2-4 though higher levels of cancer related distress in those testing 
positive are reported.3, 5 Additionally delivery of testing through a population-based model is 
acceptable and testing can be delivered in the community outside of hospital-based genetic clinics 
with high satisfaction rates.1, 5, 6 Also, the feasibility of population based genetic testing has been 
accelerated by the availability of next generation sequencing  and the decreasing costs of genetic-
testing 7. 
 
There are significant resource implications to consider around population-based BRCA1/BRCA2 
testing. Assessments of the full health economic implications are critical to inform any potential 
policy change. A health economic assessment allows for the evaluation of the overall costs and 
benefits for the genetic testing of BRCA1/BRCA2 mutations in women of differing AJ ancestry.                                       
We previously used a decision analytical model to compare the costs and consequences of 
population-based testing in AJ women ≥30 years with four AJ grandparents. The data used in this 
model was obtained from the Genetic Cancer Prediction through Population Screening (GCaPPS) 
randomised trial (ISRCTN73338115) which compared outcomes of population and FH-based 
approaches for genetic testing women with  four AJ grandparents. The model showed overall when 
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the down-stream costs of treatment were taken into account population-testing was in fact cost 
saving compared with FH-testing.8 The modelling predicted that this could lead to a significant 
reduction in breast-&-ovarian cancer incidence, and increase life-expectancy. However, our original 
analysis only applies to women with ‘four’ AJ grandparents and is not directly applicable to every 
woman with AJ ancestry as 25% UK9 and 44% USA10 Jewish marriages are to non-Jews. These women 
thus may have just one, two or three AJ grandparents and therefore the prevalence of BRCA1/BRCA2 
mutations is lower in these groups. Nevertheless these women remain at elevated BRCA risk 
compared with the general (non-Jewish) population. Cost-effectiveness data for these varying lower 
mutation prevalence levels are unavailable. This important gap in knowledge was highlighted at a 
recent meeting of experts on population-based AJ BRCA testing in Haifa, Israel, July-2016.11 We 
present an updated cost-effectiveness analysis of population BRCA1/BRCA2 testing for women with 
one, two and three AJ grandparents.  
METHODS 
 
We previously developed a decision-analytical model (Figure-1) to calculate cost-effectiveness of 
screening women with four AJ grandparents. Model structure, assumptions, analytic features, 
advantages and limitations have been described earlier.8   This model was adapted to model 
outcomes for women with differing AJ ancestry.8 Separate analyses were performed for both UK and 
USA populations. Lifetime costs and effects of genetically screening AJ women ≥30years for 
BRCA1/BRCA2 AJ founder mutations were compared with current practice of screening using FH-
based clinical criteria. 56% of BRCA carriers are missed by using family history criteria alone 
compared to population screening. Genetic counselling and genetic testing was offered to all women 
in the population screening arm and only those who fulfilled the FH-based criteria in the FH-arm. The 
criteria for FH based testing included: personal history of ovarian cancer (any age); first degree 
relative with ovarian cancer (any age); first degree relative with or personal history of breast cancer 
<50 years; first degree relative with or personal history of male breast cancer (any age).2 Parameter 
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estimates for probabilities, costs and utilities were obtained and adapted from the earlier decision 
analytical model.  
 
Probabilities 
All parameters in the decision analytical model were kept constant apart from the following three: 
Population prevalence of BRCA (P1); Probability of having a positive FH (P6); and BRCA prevalence in 
the FH-negative individuals (P8). These three parameters are influenced by change in the number of 
AJ grandparents. An individual with 3 AJ grandparents would possess 75% AJ genetic makeup and 
25% from the general population. Someone with 2 AJ grandparents would have 50% AJ and 50% 
general population makeup. Therefore, BRCA population prevalence for an individual with three, 
two or one AJ grandparents is adjusted for the relative frequency of BRCA mutations in the AJ and 
general populations. BRCA prevalence estimates for AJ is obtained from the GCaPPS study (0.0245 
(0.0131, 0.0416))2 and for the general population (0.0067 (0.00590. 0.0077)) from recent published 
estimates.12 BRCA prevalence with 3AJ grandparents=  (0.75*AJprevalence)+(0.25*General-
populationprevalence); for 2 AJ grandparents= (0.5*AJprevalence + 0.5*General-populationprevalence) and for 1 
AJ grandparent= (0.25*AJprevalence + 0.75*General-populationprevalence). The probability of having a 
strong FH, fulfilling clinical genetic testing criteria in the non-Jewish population is obtained from 
unselected control population data from the Australian Breast Cancer Family Registry. Similarly 
probability parameters P6 (having a positive FH) and P8 (Prevalence in FH-negative individuals) were 
adjusted for relative BRCA mutation frequency in AJ and general populations. This was done for all 
three parameters and their confidence intervals for all different grandparent scenarios.  The revised 
probability table for model parameters is given in Table-1. 
Quality adjusted life year (QALY) and Costs  
Utility weights express the preference of an individual in a specific health state. These weights are 
then combined with survival in life years to give a measurement known as a quality adjusted life year 
(QALY) which is the preferred value of health benefit according to the National Institute of Health & 
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Care excellence (NICE). 13 This decision-analytical model using revised estimates was run for each of 
the four scenarios: four, three, two and one AJ grandparent. The following utility scores were used 
for OC: 0.81 for early stage OC, 0.55 for advanced disease, 0.61 for recurrent disease, 0.83 for OC 
remission and 0.16 for end stage OC.14 The following utility scores, obtained from NICE guidelines15-18 
were used for BC: 0.71 for early/locally advanced BC, 0.65 for advanced disease, 0.45 for recurrence 
disease, 0.81 for BC remission and 0.16 for end stage BC. A breakdown of both UK and USA costs at 
2014/15 prices are given in Table 2. The analysis covers a health system or payer perspective. 
 
Life years 
A lifetime horizon (extending till the age of 83 years) capturing lifetime risks and consequences was 
used to model the analysis. Mean ages for BRCA1/BRCA2 related breast and ovarian cancer in AJ 
women was 43.5 years and 54.9 years were used in the analysis.  Whilst the mean ages for sporadic 
breast and ovarian cancer in AJ women were 57/62 years and 63/63 years in the UK/USA 
populations respectively.19-22 Five year survival rates, in the general UK population were used in the 
absence of AJ survival data.23 Costs, QALYs and life years were discounted at 3.5%.24 
Analysis 
To calculate the probability of being in each branch, the path probabilities of each branch were 
multiplied together.  Total costs, life years and QALYs were determined through weighting the values 
of each branch by the probability of being in each branch. To establish the cost-effectiveness of 
population based screening against FH-based testing the incremental cost-effectiveness ratio (ICER) 
was calculated by dividing differences in cost by differences in effect. The £20,000 - £30,000/QALY 
cost-effectiveness willingness to pay (WTP) threshold used by NICE 25 was used to compare the cost-
effectiveness of population-based screening in comparison to FH-based testing in the UK. A WTP 
threshold of $100,000/QALY was used for the USA analysis.26, 27 
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To account for uncertainty all model parameters, were varied simultaneously across their 
distributions using 10,000 simulations, in a probabilistic sensitivity analysis (PSA) in accordance with 
the recommendation of NICE methods guidance.28 Costs were varied by +/- 30%, confidence 
intervals were used to vary probabilities and utility scores, if available, or they were varied by +/-
10%.  Probabilities were assigned a beta distribution, costs a gamma distribution and utilities a log 
normal distribution in accordance with published literature.29  
RESULTS 
Baseline ICER results for the four different grandparent scenarios are given in Table-3 alongside 
discounted and undiscounted life years, QALYs and lifetime costs for each scenario for both UK and 
USA women. Baseline results suggest that population testing in UK women having ≥2AJ 
grandparents and ≥1 grandparent for USA women remains cost saving and highly effective 
compared with traditional testing using FH-based clinical criteria. This corresponds to a life 
expectancy gain of 15/12, 22/17, 28/22 and 33/26 days for one, two, three and four AJ grandparents 
in UK/USA women respectively. Population testing in women with just one AJ grandparent is also 
cost-effective, with an ICER= £863/QALY, and 15 days life gained. This too is well below the 
£20,000/QALY threshold, though not cost saving.  
 
The PSAs for the UK and USA (Figure-2 and Figure-3) show that for populations with four, three, two 
or one AJ grandparent(s) ≥95% of simulations are cost-effective for population screening at the 
£20,000/QALY NICE WTP and $100,000/QALY USA WTP thresholds. This suggests, compared to 
current clinical policy of FH based clinical testing, population testing in four, three, two and one AJ 
grandparent(s) is highly cost-effective.  
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DISCUSSION 
Given that a large proportion of marriages in the Jewish population are between Jews and non-Jews, 
it is important to explore the cost-effectiveness of population testing in women with differing AJ 
ancestry and BRCA prevalence rates as a consequence. Our findings confirm the cost-effectiveness of 
population based BRCA1/BRCA2 testing (compared to testing based on clinical FH criteria) in 
unselected UK & USA AJ women aged 30 and older, who have one, two or three AJ grandparents in 
addition to those with four AJ grandparents. That ≥95% PSA simulations remain cost-effective 
despite significant variability in model parameters is significant and reassuring for all UK/USA women 
with differing AJ ancestry.  This approach has the potential to reduce the number of ovarian and 
breast cancers in the AJ population. Such a programme would be cost-saving for those with four, 
three and two/ four, three, two and one AJ grandparents in the UK/USA populations respectively. 
There are not many interventions that can save both lives and money.30 AJ screening might be the 
most cost-effective and maybe the only cost-saving program among those programs that use BRCA 
testing.31 These data have important implications for population health and cancer prevention and 
are of value to healthcare providers and care commissioners. 
 
The number of days of life gained range from 15-33/12-26 days in the UK/USA. Although, these 
figures appear small, it is important to highlight that these numbers are averaged across the 
population. In health economic terms these values are significant, and for an individual in whom 
cancer is prevented this number is many folds higher. Our modelling incorporates the costs of both 
genetic testing and genetic counselling. The time horizon in our modelling is appropriately long 
enough to highlight any important variations in costs and outcomes. The sensitivity and scenario 
analyses undertaken add strength to the study. Although RRSO reduces the risk of breast cancer in 
premenopausal women, the benefit of premenopausal oophorectomy on reduction in breast cancer 
risk has recently become an issue of ongoing debate. Some Dutch investigators32 have recently 
questioned this benefit. However, the period of follow up in their analysis is short. A number of 
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other investigators have found benefit and disagree with them.33-36 Nevertheless, if we assume no 
benefit of reduction in breast cancer risk form premenopausal oophorectomy, then the ICER/QALY 
for one, two, three and four grandparents is:  £1971/$2843/QALY, £-497/$-8198/QALY, £-1715/$-
13595/QALY,  £-2420/$-16697/QALY in UK/US women respectively.  This suggests that a population 
screening approach would be cost-effective even if there were no benefit on reduction in breast 
cancer risk from premenopausal oophorectomy. Our model incorporates risk reducing mastectomy 
rates seen in the UK. However, these rates may be lower in Israeli BRCA1/BRCA2 carriers.37 Hence, 
we explored a scenario analysis at much lower risk reducing mastectomy rate of 13% reported in 
Israeli women. The discounted ICERs for a 13% risk reducing mastectomy rate are £-1958/$-
11059/QALY, £-1177/$-7548/QALY, £196/$-1255/QALY and £3056/$12103/QALY, for UK/US women 
with four, three, two and one AJ grandparents respectively. In addition, a scenario with a much 
lower RRSO uptake at 20% was explored. The discounted ICERs for this scenario in UK/US women are 
£-2589/$-17786/QALY, £-1759/$-14032/QALY, £-301/$-7366/QALY and £2793/$7110/QALY for 
women with four, three, two and one AJ grandparents. Thus population based testing in AJ women 
of differing ancestry remains cost-effective in the UK and USA even with low risk reducing 
mastectomy or low risk reducing salpingo-oophorectomy rates too. Given the wide variation in 
genetic testing costs in the US health system, we also explored thresholds for cost-effectiveness for 
population testing. We find that population testing remains cost saving for up to 2 AJ-grandparents 
(cost-effective for 1 AJ-grandparent) if the BRCA founder mutation testing costs $526/test. 
Additionally the program remains cost-effective (at the $100,000/QALY WTP threshold) for all 4 AJ 
grandparents even if the cost of a test rises till $1618, $2417, $3185 and $3934 for one, two, three 
and four AJ grandparents respectively. 
 
All surgical interventions have an associated complication rate. The complication rates reported for 
RRSO are around 4%,38 while that for risk reducing mastectomy is much higher with reports ranging 
from 30-64%39. Another limitation of the analysis is lack of adjustment for any potential negative 
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impact on quality of life after RRSO. While worse sexual functioning and vasomotor symptoms have 
been reported following RRSO, there was no difference in generic quality of life.40-42 These issues 
need to be clearly highlighted when counselling women about these procedures and incorporated 
into the informed decision making process. It is reassuring that most women report high satisfaction 
rates with surgical prevention, with satisfaction rates varying from 83% for mastectomy39 to 97% for 
oophorectomy40. 
 
Our results support the move for changing the paradigm from FH to population based BRCA1/BRCA2 
testing across the AJ population. This fulfils the necessary principles for population screening for 
genetic susceptibility of disease.43 Population testing offers the ability to maximise the opportunity 
for prevention in unaffected individuals as well as facilitate targeted precision medicine approaches 
in those who may develop cancer. This approach has been advocated by us and others.1, 8, 44, 45 It is 
also important to highlight that those with fewer grandparents but a significant FH of cancer 
(fulfilling non-Jewish general population testing criteria) particularly in non-AJ relatives, should seek 
genetic advice and not be falsely reassured. It is important to rule out the presence of a non-founder 
mutation in this situation through a full BRCA1/BRCA2 screen analysis. Additionally, our findings 
cannot be extrapolated or generalised to BRCA1/BRCA2 testing in the general non-Jewish 
population, which requires further research. Implementation of a population testing strategy will 
require wide scale propagation and dissemination of information and knowledge, working in close 
partnership with community stake holders and health professionals. Moreover, implementation 
issues related to health system delivery, referral and management pathways, logistics and control 
which can vary across different models of care in different countries remain to be ironed out.  
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Table -1: Probabilities used in the model 
Probability  Value (95%CI) [Range] Description  Source  
P1  
(4 AJ GP) 0.0245 (0.0131-0.0416) 
Population prevalence of BRCA 
FM 
GCaPPS, 
Manchanda2, 8 
P1  
(3 AJ GP) 0.0201 (0.0113-0.0331) 
BRCA prevalence with: 3AJ 
grandparents=  (0.75*AJprevalence) 
+ (0.25*General-
populationprevalence); 2 AJ 
grandparents= (0.5*AJprevalence) + 
(0.5*General-
populationprevalence); 1 AJ 
grandparent= (0.25*AJprevalence) + 
(0.75*General-
populationprevalence) 
Manchanda2, 8, 
Jervis 201512 
P1  
(2 AJ GP) 0.0156 (0.0095-0.0247) 
P1  
(1 AJ GP) 0.011 (0.0077-0.0162) 
P2 0.52 (0.39-0.67) Probability that carrier will undergo RRM Evans
46   
P3 0.96 [0.8-0.96] Reduction in risk of ovarian cancer from RRSO 
Finch47 , 
Rebbeck33  
P4 0.2987 (0.2485-0.3539) Probability that carrier without RRSO will get ovarian cancer Chen
48 
P5 
0.0185 (0.0005-0.0989) Probability that a non-carrier will get ovarian cancer CRUK  
0.0128 (0.0126-0.0130) 
Probability that a non-carrier 
will get ovarian cancer – USA 
estimate 
SEER21 
P6 
(4 AJ GP) 0.1238 (0.1043-0.1454) 
Probability of having a positive 
FH GCaPPS
2, 8 
P6 
(3 AJ GP) 0.095 (0.079-0.114) 
Probability with: 3AJ 
grandparents=  (0.75*AJprobability) 
+ (0.25*General-
populationprobability); 2 AJ 
grandparents= (0.5*AJprobability) + 
(0.5*General-
populationprobability); 1 AJ 
grandparent= (0.25*AJprobability) + 
(0.75*General-
populationprobability)  
 
P6  
(2 AJ GP) 0.0668 (0.055-0.082)   
P6  
(1 AJ GP) 0.0383 (0.0296-0.0498)  
P7 0.0938 (0.0637-0.1763) BRCA prevalence in FH positive  individuals GCaPPS
2, 8 
P8  
(4 AJ GP) 0.0203 (0.0114-0.0332) 
BRCA prevalence in FH negative  
individuals GCaPPS
2, 8 
P8 
(3 AJ GP) 0.0166 (0.0098-0.0266) 
Probability with: 3AJ 
grandparents=  (0.75*AJprobability) 
+ (0.25*General-
populationprobability); 2 AJ 
grandparents= (0.5*AJprobability) + 
(0.5*General-
populationprobability); 1 AJ 
grandparent= (0.25*AJprobability) + 
(0.75*General-
 
P8 
(2 AJ GP) 0.0129 (0.0082-0.0199)  
P8  
(1 AJ GP) 0.009 (0.006-0.013)  
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populationprobability)  
P9 0.91 (0.62-0.98) Reduction in breast cancer  risk from RRM without RRSO Rebbeck
49 
P10 0.53 (0.44-0.62) Probability that carrier without RRM will get breast cancer  Chen
48 
P11 
0.13 [0.11-0.14] 
Probability that a non-carrier 
will get breast cancer with 
screening – UK estimate 
 
CRUK50, ONS51 
0.124 (0.1236-0.1249) 
Probability that a non-carrier 
will get breast cancer with 
screening – USA estimate 
SEER22 
P12 0.55 (0.30-0.75) Probability that carrier will follow-up with RRSO Manchanda
52 
P13 0.49 (0.37-0.65) Reduction in risk of breast cancer from RRSO alone Rebbeck
33  
P14 0.95 (0.78-0.99) Reduction in risk of breast cancer from RRM with RRSO Rebbeck
49 
95%CI- 95% confidence interval, AJ- Ashkenazi Jewish, FH- family history, FM- founder 
mutations, GCaPPS- Genetic Cancer Prediction through Population Screening study; GP- 
grandparent, RRSO- risk reducing salpingo-oophorectomy, RRM: Risk reducing Mastectomy 
Explanation: 
The probabilities P1, P6 and P8 have been adapted for different levels of AJ ancestry: four, 
three, two and one grandparent. The other model probabilities remain the same as 
previously published.8 
P1: The probability of carrying a BRCA FM in the AJ population (p1= 0.0245) is taken from the 
GCaPPS study. This is the probability with 4 AJ grandparents. The probability of having a BRCA 
mutation in the non-Jewish population (0.0067 (0.00590. 0.0077) is taken from up to date 
estimates from Jerivs 2015. BRCA prevalence with: 3AJ grandparents=  (0.75*AJprevalence) + 
(0.25*General-populationprevalence); 2 AJ grandparents= (0.5*AJprevalence) + (0.5*General-
populationprevalence); 1 AJ grandparent= (0.25*AJprevalence) + (0.75*General-populationprevalence) 
P2: The probability that BRCA1/2 carrier will undergo RRM is taken is taken from an analysis 
of UK BRCA1/2 carriers by Evans et al 2009. A composite uptake rate (p2=0.52) for BRCA1 
(60% RRM rate) and BRCA2 (43% RRM rate) carriers  weighted for the relative prevalence of 
BRCA1 and BRCA2 FM found in the London AJ population was computed.46 
P3: The reduction in ovarian cancer risk obtained from RRSO (p3= 0.96) is taken from 
previous studies which report a 4% residual-risk of primary peritoneal cancer following 
RRSO.47  
P4: The GCaPPS model8 uses ovarian cancer penetrance estimates (40% for BRCA1, 18% for 
BRCA2) from a meta-analysis, corrected for ascertainment.48 To simplify the analysis the 
GCaPPS model used a composite risk for BRCA1 and BRCA2 carriers weighted for the relative 
prevalence of BRCA1 and BRCA2 FM. The overall risk of ovarian cancer in BRCA carriers is 
calculated as ((0.0132*0.4)/2.45 + (0.0113*0.18)/2.45).8 
P5: The risk of ovarian cancer in a low-risk population (p5= 0.0185) is obtained from Cancer 
Research UK53 for UK women and SEER data21 was used for USA women. 
P6: The probability of having a strong FH of cancer fulfilling the current clinical criteria (FH-
positive) for women with four AJ grandparents is obtained from the GCaPPS study.2, 8 The 
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probability of having a positive FH fulfilling non-AJ genetic-testing criteria is obtained from 
previously unpublished unselected control population data from the Australian Breast Cancer 
Family Registry (ABCFR). The probability for three, two and one grandparent is adjusted for 
the relative prevalence in Jewish and general populations. The Probability with: 3AJ 
grandparents=  (0.75*AJprobability) + (0.25*General-populationprobability); 2 AJ grandparents= 
(0.5*AJprobability) + (0.5*General-populationprobability); 1 AJ grandparent= (0.25*AJprobability) + 
(0.75*General-populationprobability) 
P7: The BRCA prevalence in FH-positive individuals is also obtained from GCaPPS2, 8  
P8: The BRCA prevalence in FH-negative individuals for women with four AJ grandparents is 
obtained from the GCaPPS study2, 8 The probability for three, two and one grandparents is 
adjusted for the relative prevalence in Jewish and general populations. The Probability with: 
3AJ grandparents=  (0.75*AJprobability) + (0.25*General-populationprobability); 2 AJ grandparents= 
(0.5*AJprobability) + (0.5*General-populationprobability); 1 AJ grandparent= (0.25*AJprobability) + 
(0.75*General-populationprobability) 
P9: Reduction in breast cancer risk from RRM in BRCA carriers not undergoing RRSO is taken 
from the PROSE study data by Rebbeck et al, JCO 2004.49 
P10: The breast cancer penetrance for BRCA carriers (57% for BRCA1 and 49% for BRCA2) is 
taken from a meta-analysis, corrected for ascertainment.48 To simplify the analysis the 
GCaPPS model used a composite risk for BRCA1 and BRCA2 carriers weighted for the relative 
prevalence of BRCA1 and BRCA2 FM (GCaPPS study). The overall risk of breast cancer in BRCA 
carriers is calculated as ((0.0132*0.57)/2.45 + (0.0113*0.49)/2.45).2, 8 
P11: The risk of breast cancer in a low risk population is taken from Cancer Research UK and 
UK Office for National Statistics data,50, 51 and from SEER data22 for USA women 
P12: In the GCaPPS model8 we have used the RRSO rates reported in high-risk women from 
London which reflects the views of carriers from a London population and is within the range 
reported in the literature.52 
P13: The reduction in breast cancer risk in pre-menopausal women undergoing RRSO is taken 
from a meta-analysis by Rebbeck et al.33 
P14: Reduction in breast cancer risk from RRM in BRCA carriers undergoing RRSO is taken 
from the PROSE study data by Rebbeck et al, JCO 2004.49 
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Table 2: Costs used in the model (2014 prices) 
Item Cost UK 
(£) 
Cost USA 
($) 
Source 
Cost of BRCA Founder 
mutation testing  
50 300 GCaPPS2 
Cost of genetic counselling  43 41 GCaPPS,2 PSSRU Unit costs of Health and 
Social Care54 , Schwartz, 201455 
Cost of RRSO (and HRT and 
osteoporosis prevention) 
3411 8144 NHS Reference costs,56 BNF57 
Cost of ovarian cancer 
diagnosis and treatment 
14123 127,995 NHS Reference costs,56 NICE guideline58 
Yearly cost of ovarian 
cancer treatment year 1-2 
10050 14,071 NHS Reference costs,56 NICE guideline58 
CRUK59 Grann 201160 
Yearly cost of ovarian 
cancer treatment year 3-5 
14387 14,071 NHS Re.ference costs,56 NICE guideline58 
CRUK59 Grann 201160 
Terminal care costs with 
ovarian cancer 
15450 89,424 National Audit office61 Incisive Health report 
for CRUK62 Grann 201160 
Cost of risk reducing 
mastectomy 
3901 12,596 NHS reference cost,56 weighted for 21% 
complication rate4 Grann 201160 
Cost of breast screening 347 1534 Robertson 2011,63 NHS Reference costs56 
CDC guideline64 
Cost of breast screening 
BRCA carriers 
4582 33,530 NHS Reference costs56, NICE guideline65  
CDC guideline,64 Grann 201160 
Cost of breast cancer 
diagnosis and treatment 
15527 82,030 NHS Reference costs56, NICE guideline16, 
NICE guideline15, Grann 201160 
Yearly cost of breast 
cancer treatment  
2008 7738 NHS Reference costs56, Robertson 201163, 
BNF57, NICE guideline16, NICE guideline15, 
Implementing NICE guidance16 Grann 201160 
Yearly cost of BRCA 
associated breast cancer 
1917 7738 NHS Reference costs56, Robertson 201163, 
BNF57, NICE guideline16, NICE guideline15, 
Implementing NICE guidance16 Grann 201160 
Terminal care costs with 
breast cancer 
15,450 65,403 National Audit office,61 Grann 201160 
BNF – British National Formulary, GCaPPS – Genetics Cancer Prediction through Population 
Screening study, HRT – hormone replacement therapy, NHS – National Health Service, NICE – 
National Institute for Health and Clinical Excellence, PSSRU – Personal Social Services Research 
Unit, RRSO – risk reducing salpingo-oophorectomy, RRM – risk reducing mastectomy  
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Explanation 
Cost of RRSO: It is assumed HRT is provided to women from the age they have RRSO until the age 
of menopause (51 years).57 An 80% compliance rate is assumed with HRT, and these costs are 
added to costs for surgery. For the UK RRSO costs are for an upper genital tract 
laparoscopic/endoscopic intermediate procedure.56 To monitor bone health, the cost of three 
DEXA scans and calcium and vitamin-D3 are also included. USA prophylactic salpingo-
oophorectomy costs are taken from Grann 201160 and inflated using the medical component of 
the USA consumer price index. 
Ovarian Cancer Costs:  
Based on ovarian cancer guideline published by NICE.58 Diagnosis costs include ultrasound scan, 
pelvic examination, CT scan, CA125 test, percutaneous biopsy and peritoneal cytology. 
Costs of treatment include reference cost for lower and upper genital tract complex major 
procedure and 6 cycles of carboplatin and paclitaxel chemotherapy administration. Survivors were 
assumed to have three consultant visits, 4 CA125 tests and a CT scan each year for the first two 
years post-surgery. In years 3 to 5 post surgery, survivors were assumed to have 2 consultant 
visits and 2 CA125 tests. Terminal cancer costs are taken from a report submitted to the National 
Audit Office, UK.61 Recurrent ovarian cancer costs are taken from a report commissioned by 
CRUK.62 For the USA, the cost of ovarian cancer diagnosis, treatment, recurrence and terminal 
ovarian cancer costs is taken from Grann 201160 and inflated using the medical component of the 
USA consumer price index. 
Breast Cancer Costs:  
Based on NICE guidelines on early/locally advanced breast cancer16 and advanced breast cancer in 
UK15; the BNF57 and Department of Health NHS reference costs56. 
Cost of breast screening in general population: women between 50-70years are offered 
mammography every three years in accordance with the UK NHS breast cancer screening 
program.66 
Cost of diagnosis based on clinical examination, ultrasound, mammography and biopsy. 
Cost of breast screening in carriers: women are offered an annual MRI from 30-49 years and an 
annual mammogram from 40-69 years in accordance with NICE familial breast cancer guidelines.65 
Cost of breast cancer treatment: in non-carriers, 10% of breast cancer is non-invasive DCIS and 
90% invasive. 95% of invasive breast cancer is early and locally advanced with 5% being advanced 
breast cancer.16 In BRCA1/2 carriers 20% are non-invasive DCIS and 80% invasive.4, 67 
Yearly cost of breast cancer treatment: includes costs of sentinel lymph node biopsy and axillary 
lymph node dissection as recommended in NICE guideline.16 Breast conserving surgery and 
mastectomy costs with reconstruction are included in treatment costs.56  Radiotherapy costs are 
included that are offered for early invasive/locally advanced cancer whilst chemotherapy is 
offered alongside radiotherapy for advanced cancers.  
Chemotherapy costs are taken from NICE guidelines based on 1st and 2nd line 15, 16 
polychemotherapy.68 Costs take into account the difference in stage at presentation with 20% of 
cancers being non-invasive. 
26 
 
Costs are also taken into account for the testing cancers that are ER positive and HER2 positive in 
the general and BRCA carrier population. 70% general population invasive breast cancers are ER 
positive; 15% early invasive breast cancers and 25% advanced breast cancers are HER2 positive.15, 
16 ER positive cancers receive Tamoxifen at 20mg/day if premenopausal or Anastrazole 1mg/day is 
postmenopausal for 5 years, costs of both are from the BNF.57 To offset the risk of developing 
bone metastases, 65% of individuals are offered bisphosphonates. Per NICE guidelines, it is 
assumed 50% of those will receive intravenous zolendronic acid or pamidronate and the other 
50% receiving oral clodronate and ibandronic acid. As per NICE guidelines, HER2 positive patients 
are given trastuzumab at 3 weekly intervals for a year or until disease recurrence.16 Recurrence 
rates are included for breast cancer as obtained through the USA National Surgical Adjuvant 
Breast and Bowel Project.69, 70 
Follow up costs for breast cancer include, six monthly consultations and annual mammograms 
with MRI scans for stage 4 cancers. Costs take into account a 35% progression rate from early and 
locally advanced to advanced disease16 and 66% relapse rate in advanced disease.71 Terminal 
cancer care costs were obtained from a report published by the National Audit Office, UK.61   
USA Breast Cancer Costs:  The cost of breast cancer diagnosis and treatment is taken from Grann  
201160 and inflated using the medical component of the USA consumer price index. Cost of breast 
screening in non-carriers: assumes mammograms are conducted every two years from the age of 
50 (CDC guidelines)64. Cost of breast screening in carriers: assumes USA women are offered a 
yearly mammography and MRI from the age of 30 years and then from 50 years onwards women 
are only offered an annual mammography.64 
Terminal breast cancer costs are taken from Grann 201160 and inflated using the medical 
component of the USA consumer price index. 
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Table 3: Model outcomes for costs, life-years and quality adjusted life-years (QALYs), for UK and 
USA  
AJ 
grand
parent
s 
 
Screening arms 
UK Results USA Results 
Cost, £ 
Life 
years* QALYs  Cost, $ 
Life 
years* QALYs  
4 
Average population screening  1861 52.26 23.15 7254 52.59 23.24 
Average family history screening  1955 52.17 23.12 7775 52.51 23.22 
Incremental (difference) -94 0.090 0.032 -522 0.072 0.027 
ICER per QALY -2960   -19587   
3 
Average population screening  1813 52.27 23.16 7038 52.60 23.25 
Average family history screening  1875 52.19 23.13 7413 52.53 23.22 
Incremental (difference) -62 0.075 0.027 -375 0.061 0.022 
ICER per QALY  -2327   -16788   
2 
Average population screening  1766 52.28 23.16 6822 52.61 23.25 
Average family history screening  1792 52.22 23.14 7033 52.56 23.23 
Incremental (difference) -26 0.060 0.021 -212 0.048 0.018 
ICER per QALY -1254   -12013   
1 
Average population screening  1718 52.29 23.17 6606 52.62 23.26 
Average family history screening  1705 52.25 23.15 6637 52.58 23.24 
Incremental (difference) 13 0.042 0.015 -31 0.034 0.012 
ICER per QALY 863   -2542   
 
ICER – Incremental Cost-effectiveness Ratio, QALY – Quality Adjusted Life Years 
*Undiscounted outcomes shown for life years. Costs and QALY outcomes are discounted 
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Figure1: Decision Model Structure 
 
 
 
Figure 1: 
The upper part of the model structure reflects a population-based approach to BRCA testing and the 
lower part of the model depicts a FH-based approach. Each decision point in the model is called a 
‘node’ and each path extending from a node is called a decision ‘branch’. Each branch represents a 
mutually exclusive course or outcome. Each decision is given a probability (probabilities ‘p1 to p14’ 
used in the model are explained in Table1) highlighted in a white box along the decision branch. 
Values for each outcome are calculated. Cancer incidence was estimated by summing the 
probabilities of pathways ending in ovarian or breast cancer. Final outcomes (blue boxes on the right 
of the figure) of each path include development of breast cancer (BC), ovarian cancer (OC) and no 
breast/ovarian cancer (no OC or BC).  BC- Breast Cancer, OC-Ovarian Cancer; No OC or BC- No 
Ovarian Cancer or Breast Cancer developed., RRSO –Risk reducing salpingo-oophorectomy; RRM – 
Risk reducing mastectomy.  
Manchanda, R et al; Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi 
Jewish Women Compared With Family History–Based Testing, Journal of the National Cancer 
Institute, 2014, 107, 1, by permission of Oxford University Press. 
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Figure 2: UK Probabilistic Sensitivity Analysis for varying Ashkenazi Jewish grandparent ancestry 
 
 
Figure 2: Cost-effectiveness acceptability curves generated when the model undergoes probabilistic 
sensitivity analysis. In the probabilistic sensitivity analysis all model parameters are varied 
simultaneously across their distributions. Each of the four scenarios (4, 3, 2, 1 grandparents) were 
simulated 10,000 times and the results shown are the proportion of these simulations which would 
be cost-effective at different willingness-to-pay thresholds. X-axis: Incremental cost-effectiveness 
ratio (ICER) in terms of Cost (£s)/QALY; Y-axis: Proportion of simulations. The solid red line marks the 
proportion of simulations found to be cost-effective at the £20,000 threshold used by NICE. ≥95%, 
simulations are cost effective for varying levels of Jewish ancestry in this analysis. 
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Figure 3: USA probabilistic Sensitivity Analysis for varying Ashkenazi Jewish grandparent ancestry 
 
 
Figure 3: USA cost-effectiveness acceptability curves generated when the model undergoes 
probabilistic sensitivity analysis. In the probabilistic sensitivity analysis all model parameters are 
varied simultaneously across their distributions. Each of the four scenarios (4, 3, 2, 1 grandparents) 
were simulated 10,000 times and the results shown are the proportion of these simulations which 
would be cost-effective at different willingness-to-pay thresholds. X-axis: Incremental cost-
effectiveness ratio (ICER) in terms of Cost ($s)/QALY; Y-axis: Proportion of simulations. The solid red 
line marks the proportion of simulations found to be cost-effective at the $100,000 threshold. ≥95%, 
simulations are cost effective for varying levels of Jewish ancestry in this analysis.  
 
 
 
 
 
